Fintel reports that on April 6, 2023,
Oppenheimer
reiterated
coverage of Simulations Plus (NASDAQ:SLP) with
a Outperform recommendation.
Analyst Price Forecast Suggests 41.67% Upside
As of April 6, 2023,
the average one-year price target for Simulations Plus is $59.92.
The forecasts range from a low of $44.44 to a high of $73.50.
The average price target represents an increase of 41.67% from its latest reported closing price of $42.30.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Simulations Plus
is $62MM, an increase of 13.49%.
The projected annual non-GAAP EPS
is $0.65.
What are Other Shareholders Doing?
Mutual of America Variable Insurance Portfolios, Inc. – Small Cap Growth Portfolio Class
holds 2K shares
representing 0.01% ownership of the company.
In it’s prior filing, the firm reported owning 2K shares, representing
a decrease
of 7.66%.
The firm
decreased
its portfolio allocation in SLP by 27.71% over the last quarter.
QVMS – Invesco S&P SmallCap 600 QVM Multi-factor ETF
holds 2K shares
representing 0.01% ownership of the company.
In it’s prior filing, the firm reported owning 2K shares, representing
an increase
of 5.26%.
The firm
decreased
its portfolio allocation in SLP by 33.89% over the last quarter.
Wipfli Financial Advisors Llc
holds 0K shares
representing 0.00% ownership of the company.
Louisiana State Employees Retirement System
holds 8K shares
representing 0.04% ownership of the company.
No change in the last quarter.
Citigroup
holds 11K shares
representing 0.05% ownership of the company.
In it’s prior filing, the firm reported owning 8K shares, representing
an increase
of 24.63%.
The firm
increased
its portfolio allocation in SLP by 11.16% over the last quarter.
What is the Fund Sentiment?
There are 393 funds or institutions reporting positions in Simulations Plus.
This is a decrease
of
29
owner(s) or 6.87% in the last quarter.
Average portfolio weight of all funds dedicated to SLP is 0.12%,
a decrease
of 15.59%.
Total shares owned by institutions decreased
in the last three months by 1.09% to 19,459K shares.
The put/call ratio of SLP is 0.42, indicating a
bullish
outlook.
Simulations Plus Background Information
(This description is provided by the company.)
Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With its subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. The company’s technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide.
See all Simulations Plus regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
